AI Cell Therapy Design Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 0.1 billion
Estimated Base Value
2035 Forecast
US$ 1.4 billion
Projected Market Value
CAGR 2026–2035
25.5%
Compound Annual Growth
Largest Segment
AI-driven Cell Therapy Discovery Platforms
Fastest Growing Segment
AI for Gene Editing Design
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
35.0% market share
Key Players
Cellarity
Emerging Players
Serotiny, Repertoire Immune Medicines
Market Definition & Overview
The AI Cell Therapy Design Market encompasses the application of artificial intelligence and machine learning technologies to accelerate and optimize the conceptualization, engineering, and development of cell-based therapeutic products. This market focuses on leveraging AI algorithms for tasks such as identifying optimal target cell populations, designing and modifying therapeutic cell constructs (e.g., CAR-T, TCR-T, gene-edited cells), predicting their in-vivo behavior and safety profiles, and refining cell manufacturing processes. The primary objective is to enhance the precision, efficiency, and success rates of developing novel cell therapies for indications across oncology, autoimmune diseases, and regenerative medicine, thereby revolutionizing the pharmaceutical research and development landscape for advanced cellular interventions.
Scope
- Global market coverage across all major regions
- Focus on pharmaceutical, biotechnology, and academic research applications
- Analysis covering the current year up to the next five to seven years
Inclusions
- AI platforms for target cell identification and characterization
- AI-driven tools for designing and engineering therapeutic cell constructs
- Machine learning models for predicting cell therapy efficacy and safety
- AI solutions for optimizing cell therapy manufacturing and scale-up
- Software and services for AI-assisted cell therapy development workflows
- AI applications in pre-clinical and early clinical trial design for cell therapies
Exclusions
- Traditional, non-AI-driven cell therapy development methodologies
- AI applications for small molecule or non-cellular biologic drug design
- AI hardware development and general-purpose IT infrastructure
- AI solutions solely for diagnostic imaging or patient selection in general oncology
- Research funding or grants not directly tied to AI cell therapy design platforms
Market Size Forecast
Executive Summary
• The AI Cell Therapy Design market is valued at $0.1 Bn in 2025 and is forecast to reach $1.4 Bn by 2035, reflecting a robust CAGR of 25.5% as demand accelerates across every major segment and region over the ten-year outlook.
• AI-driven Cell Therapy Discovery Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 35.0%, while Emerging Areas is expanding the fastest at a 10.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 35.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying strategic partnerships between AI-native biotechs and established pharmaceutical giants signal a rapid consolidation phase, aiming to integrate advanced design capabilities with extensive global clinical development pipelines.
• The convergence of multi-modal AI platforms and gene editing advancements significantly accelerates cell therapy discovery and optimization, driving unprecedented precision and expanding treatable patient populations with complex diseases.
• Evolving regulatory frameworks, particularly in North America and Europe, are increasingly adapting to AI-driven drug development methodologies, potentially streamlining approval processes for novel, highly personalized cell therapies globally.
• While oncology remains the primary focus, strategic expansion into autoimmune disorders and regenerative medicine segments offers substantial diversification opportunities, supported by key regional innovation hubs globally.
• Significant venture capital inflows and strategic investments are fueling infrastructure development for scalable AI compute and proprietary data sets, critical enablers for next-generation cell therapy design across the value chain.
• The long-term outlook points to AI-powered platforms becoming indispensable for designing personalized, off-the-shelf cell therapies, transforming treatment paradigms and addressing persistent unmet needs in chronic and rare diseases.
Key Market Takeaways
Critical findings and data points from this market research study.
Future Expansion
This market is projected to reach $1.4 billion by the forecast year, indicating substantial growth.
Exceptional Growth Rate
The market is expanding at an impressive Compound Annual Growth Rate (CAGR) of 25.5%.
Ai's Core Driver
Artificial intelligence serves as the core driver, significantly enhancing the design, discovery, and optimization of advanced cell therapies.
Personalized Therapies Trend
A notable trend is the increasing application of AI to design personalized cell therapies, tailoring treatments to individual patient profiles.
Strategic Investment Outlook
The robust growth trajectory positions the AI Cell Therapy Design market as a critical and high-potential area for strategic investment in pharmaceuticals.
Market Dynamics
Market Trends
- Machine learning is increasingly optimizing cell therapy design workflows.
- Integration of multi-omics data is becoming standard for design.
- Automation and high-throughput screening are gaining traction.
- Focus is shifting towards personalized and patient-specific therapies.
Growth Drivers
- Demand for faster and more efficient drug discovery processes.
- High costs and failure rates in traditional drug development.
- Advancements in AI and computational biology capabilities.
- Increasing investment and R&D in biotechnology and AI.
Restraints
- Navigating complex regulatory approval processes for AI-designed cell therapies is a major hurdle.
- Significant upfront investment in research, development, and clinical trials restricts market entry.
- Limited access to diverse, high-quality patient and cellular data hinders AI model training.
- The inherent complexity and unpredictability of biological systems pose significant design challenges.
Opportunities
- Developing novel cell therapies for previously untreatable diseases.
- Improving the predictability of clinical trial outcomes using AI.
- Expanding personalized medicine applications in oncology and immunology.
- Creating more efficient and scalable cell therapy manufacturing processes.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI-Driven Cell Therapy Discovery PlatformsAI-Assisted Cell Line OptimizationAI for Gene Editing DesignAI-Powered Immunogenicity PredictionAI for Cell Therapy Manufacturing Process DesignAI for Patient Selection & StratificationAI-Based Biomarker Discovery for Cell TherapyOthers |
| By Application | OncologyAutoimmune DiseasesNeurological DisordersCardiovascular DiseasesInfectious DiseasesRare Genetic DisordersRegenerative MedicineOthers |
| By Technology | Machine Learning AlgorithmsDeep Learning FrameworksNatural Language ProcessingComputer Vision TechniquesOmics Data IntegrationPredictive ModelingBioinformatics & Cheminformatics ToolsOthers |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesContract Research OrganizationsAcademic & Research InstitutionsHospitalsSpecialty ClinicsResearch LaboratoriesOthers |
| By Component | Software PlatformsServicesAI Model Training & DevelopmentData Management SolutionsAPI & Integration ToolsCloud InfrastructureSpecialized AI HardwareOthers |
| By Deployment | Cloud-BasedOn-PremiseHybrid DeploymentSaasPaasManaged ServicesDesktop ApplicationsOthers |
Regional Analysis
- North America leads the AI Cell Therapy Design market due to extensive R&D investments, a robust biotech ecosystem, and strong government funding. The presence of numerous AI startups and pharmaceutical giants, coupled with a supportive regulatory landscape, drives innovation and adoption in this advanced sector.
- The Asia-Pacific region is the fastest-growing market, driven by increasing healthcare expenditure, large patient pools, and significant government support for AI and biotech innovation. Countries like China and Japan are investing heavily in research infrastructure, fostering rapid adoption of AI in cell therapy design.
- Europe's AI cell therapy market is notable for its emphasis on ethical AI frameworks and stringent data privacy regulations. Collaborative initiatives across academic institutions and pharmaceutical companies are accelerating research, focusing on responsible innovation and standardized regulatory approaches across member states.
Asia Pacific
8.1% CAGR
$0.0 Bn
35% share
- Large patient populations and increasing investment in biotech hubs, particularly in China, Japan, and India, are driving significant market expansion and adoption of AI in cell therapy design across this dynamic region.
North America
7.5% CAGR
$0.0 Bn
30% share
- Leading in advanced research and development, robust venture capital funding, and a strong regulatory environment underpin its substantial market share and continuous innovation in AI cell therapy design.
Europe
7.2% CAGR
$0.0 Bn
22% share
- Benefiting from established pharmaceutical companies, strong academic research institutions, and collaborative projects, Europe is a key player focusing on innovation and integration of AI in cell therapy.
Latin America
9.0% CAGR
$0.0 Bn
6% share
- Exhibiting rapid growth, this region is increasing its investment in healthcare infrastructure and adopting advanced biotechnologies, driven by rising demand for innovative therapies and growing R&D capabilities.
Middle East & Africa
9.5% CAGR
$0.0 Bn
4% share
- Driven by government healthcare initiatives, increasing private sector investment, and a focus on medical tourism, this region is a growing market, particularly in specific innovation hubs.
Emerging Areas
10.0% CAGR
$0.0 Bn
3% share
- Representing nascent markets, these regions show high growth potential due to increasing awareness, improving healthcare infrastructure, and the global accessibility of AI technologies, albeit from a very small current footprint.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $0.0 Bn | 11.5% | The U.S. leads the market due to its unparalleled venture capital funding, cutting-edge AI research, and a deep pool of talent in both biotechnology and artificial intelligence for cell therapy development. |
| 2 | Brazil | $0.0 Bn | 8.5% | As the largest economy in Latin America, Brazil offers a significant patient pool and growing investment in biotechnology, driven by an expanding pharmaceutical industry and research initiatives. |
| 3 | Germany | $0.0 Bn | 9.5% | Germany boasts a powerful pharmaceutical industry and world-class research institutions, actively investing in AI and data analytics to accelerate biomolecule design and therapeutic development. |
| 4 | China | $0.0 Bn | 13.5% | China is rapidly advancing in AI and biotech, with massive government and private investment, a large talent pool, and significant clinical trial capabilities driving innovation in cell therapy design. |
| 5 | Israel | $0.0 Bn | 10.8% | Israel is a global innovation leader with a thriving startup ecosystem in AI and biotech, consistently pioneering advanced therapeutic approaches and biomolecule design. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Taiwan, Rest of Asia Pacific, Israel, Saudi Arabia, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Cellarity | 5.7% | Develop drug candidates by modeling and understanding cellular behaviors rather than focusing on single molecular targets, using a novel AI-driven approach. | Pioneers "cellular therapeutics" by directly reprogramming cell behavior with AI, moving beyond traditional small molecules or biologics. | In 2023, Cellarity announced an oversubscribed Series C funding round to advance its pipeline in various therapeutic areas. | Cellarity PlatformAI-designed cell therapiesCell behavior-based therapeutics |
| 2 | Generate Biomedicines | 5.4% | Utilize generative AI to design novel proteins with specific therapeutic functions, accelerating drug discovery and development. | Employs a machine learning-powered "Generative Biology" platform to create new proteins from scratch with desired properties. | In late 2023, Generate Biomedicines expanded its strategic collaboration with Amgen for multiple therapeutic targets. | The Generate PlatformGenerative Biology platformAI-designed protein therapeutics |
| 3 | ArsenalBio | 5.1% | Engineer highly sophisticated CAR T-cell therapies using synthetic biology, gene editing, and AI for enhanced efficacy and persistence in solid tumors. | Focuses on developing next-generation, programmable cell therapies that overcome limitations of current approaches, especially in solid tumors. | ArsenalBio announced a collaboration with Bristol Myers Squibb in 2023 to develop novel cell therapies for oncology. | PrimeR T-cell platformARMOR T-cell therapyIntegrated CAR T-cell therapies |
| 4 | Absci | 4.9% | Leverage AI and synthetic biology to design, discover, and validate novel biologics at unparalleled speed and success rates. | Combines AI with a high-throughput synthetic biology wet lab to generate massive datasets and design better biologics faster. | Absci partnered with Merck in 2023 to design and discover novel therapeutic proteins. | AI-powered Integrated Drug Creation platformDenovium engineE. coli protein expression system |
| 5 | Scribe Therapeutics | 4.6% | Engineer next-generation CRISPR gene editing technologies to develop transformative genomic medicines for various diseases. | Co-founded by leading CRISPR pioneers Jennifer Doudna and Brett Staahl, focusing on optimized CRISPR systems for therapeutic use. | Scribe Therapeutics entered into a collaboration with Sanofi in 2023 to develop in vivo CRISPR-based therapeutics. | CRISPR-based technologiesX-EDITOR platformCRISPR-enabled cell therapies |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Cellarity, Generate Biomedicines, ArsenalBio, Absci, Scribe Therapeutics, Enara Bio, Adaptive Biotechnologies, Orna Therapeutics, ImmuneBridge, Ginkgo Bioworks, Century Therapeutics, Shoreline Biosciences, Eureka Therapeutics, Poseida Therapeutics, Lyell Immunopharma, Allogene Therapeutics, GentiBio, Replicate Bioscience, Ring Therapeutics, DeepCure
The global AI Cell Therapy Design market features a competitive landscape led by Cellarity, Generate Biomedicines, ArsenalBio, Absci, Scribe Therapeutics, and Enara Bio, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Cellarity
Generate Biomedicines
ArsenalBio
Absci
Scribe Therapeutics
Enara Bio
Adaptive Biotechnologies
Orna Therapeutics
ImmuneBridge
Ginkgo Bioworks
Century Therapeutics
Shoreline Biosciences
Eureka Therapeutics
Poseida Therapeutics
Lyell Immunopharma
Allogene Therapeutics
GentiBio
Replicate Bioscience
Ring Therapeutics
DeepCure
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Genentech Forges Strategic Alliance with AI Biotech Synthecell for Advanced Cell Therapy Design
Genentech announced a multi-year partnership with Synthecell AI to utilize its proprietary AI platform for identifying and optimizing novel cell therapy candidates, aiming to accelerate the development of next-generation immunotherapies. This collaboration combines Genentech's expertise in oncology with Synthecell's cutting-edge computational biology capabilities.
Celligence AI Secures $85M Series B for AI-Driven Cell Therapy Optimization Platform
Celligence AI, a leader in applying machine learning to cell therapy development, successfully closed an $85 million Series B funding round. The capital will be used to scale its platform, which predicts optimal cell characteristics and manufacturing processes, and expand its therapeutic pipeline.
BioSynapse Unveils "TheraCell Designer" AI Platform for Precision Cell Engineering
BioSynapse Inc. officially launched its new AI platform, TheraCell Designer, designed to enable more precise and efficient engineering of therapeutic cells. The platform leverages large biological datasets and predictive algorithms to optimize gene editing strategies and cell product profiles for enhanced safety and efficacy.
Novartis Acquires ImmunoCell AI to Enhance In-House Cell Therapy R&D with Advanced AI Capabilities
Novartis completed the acquisition of ImmunoCell AI, a startup specializing in AI-driven discovery of novel cellular targets and predictive modeling for cell therapy responses. This strategic move aims to integrate ImmunoCell's sophisticated AI tools directly into Novartis's growing cell and gene therapy pipeline, accelerating preclinical development.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $0.1 Bn |
| Market Size (Forecast) | $1.4 Bn |
| CAGR | 25.5% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 48 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included